SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Down 60.5% in December

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the target of a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 1,700 shares, a decrease of 60.5% from the November 30th total of 4,300 shares. Based on an average daily volume of 16,200 shares, the short-interest ratio is presently 0.1 days.

SAB Biotherapeutics Stock Performance

Shares of SAB Biotherapeutics stock opened at $0.08 on Friday. The business has a 50 day moving average of $0.06 and a 200 day moving average of $0.05. SAB Biotherapeutics has a 52 week low of $0.01 and a 52 week high of $0.19.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.